Loading...

Margaret Tempero, MD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentMedicine
Phone415-353-7528
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of NebraskaM.D.1977School of Medicine
    Collapse Awards and Honors
    UCSF2012  - PresRombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science
    UCSF2000  - 2012Doris and Don Fisher Distinguished Professor in Clinical Research
    Journal Nat'l Comprehensive Cancer Network2014  - PresEditor-In-Chief

    Collapse Overview 
    Collapse Overview
    Dr. Tempero is Director, UCSF Pancreas Center and Leader, Pancreas Cancer Program. Her research career has focused on pancreatic ductal adenocarcinoma especially in the area of investigational therapeutics. She was a pioneer in the use of antibody-based therapies and helped develop the fixed dose rate concept for gemcitabine. Her group has developed effective gemcitabine combinations and provided a foundation for using CA19-9 as a surrogate for survival in clinical trials. Currently her group is assessing molecular subtypes and molecular enrichment for selecting new drugs for clinical evaluation.

    Dr. Tempero directed the first GI SPORE devoted to pancreatic cancer when she was on the faculty of the University of Nebraska and subsequently led the NCI funded U54 Molecular Target Assessment Team at UCSF. She also organized the first Pancreas Cancer Think Tank in 1999 and co-led the NCI sponsored Progress Review Group on Pancreatic Cancer in 2000. She has served as the Chair of the NCCN Guidelines Panel on Pancreatic Cancer since 2000. She also serves on the Pancreatic Cancer Task Force for the NCI intergroup and recently co-organized the State of the Science meeting on pancreatic cancer at the NCI.

    Dr. Tempero also has extensive experience in scientific review and administration, training and oversight. She co-directed the AACR/ASCO Methods in Clinical Cancer Research in Vail for 3 years and spent 9 years of service teaching this course and similar courses in Europe and Australia. She was founding Chair of the NCI Clinical Oncology Study Section (CONC) and served as a member and Chair (2-year term) of the NCI Board of Scientific Counselors Subcommittee A. She is on the External Advisory Boards of the Pancreas SPORE at MDACC and the GI SPOREs at the University of Arizona and Northwestern. She is, or has been, on the Scientific Advisory Boards of the Lustgarten Foundation, the Pancreatic Cancer Action Network, the V Foundation, The Alberta Canada Cancer Board and the EORTC. She has held many appointments at AACR and ASCO and has served as a member of the ASCO Board of Directors and as ASCO President in 2004. She recently served as a member of the Oncology Drug Advisory Committee for the FDA. She served as Deputy Director and Interim Director for the UNMC Eppley Cancer Center until 1999, Chief Emeritus of the Division of Medical Oncology at UCSF (2000 – 2007) and Deputy Director and Director of Research Programs at the UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) from 2000 to 2012.


    Collapse Research 
    Collapse Research Activities and Funding
    Perioperative Stromal Depletion Strategies in Pancreatic Ductal Adenocarcinoma
    NIH/NCI R21CA184429Sep 15, 2014 - Aug 31, 2016
    Role: Principal Investigator
    Mechanism-Based Evaluations of ErbB-Targeted Agents
    NIH/NCI U54CA090788Sep 26, 2001 - Dec 31, 2008
    Role: Principal Investigator
    Cancer Center Support Grant
    NIH/NCI P30CA082103Aug 5, 1999 - May 31, 2018
    Role: Co-Investigator
    SPORE IN GASTOINTESTINAL CANCER
    NIH/NCI P50CA072712Sep 1, 1997 - Jan 31, 2005
    Role: Co-Principal Investigator
    DEFINING TOXICITY AND BENEFIT FOR RADIOIMMUNOTHERAPY
    NIH/NCI U01CA058272Sep 30, 1993 - Sep 29, 2000
    Role: Principal Investigator
    Fred & Pamela Buffett Cancer Center Support Grant
    NIH/NCI P30CA036727Jul 1, 1984 - Jul 31, 2021
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Global Health
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Tempero M. Genomic Medicine Takes the Stage, Again! J Natl Compr Canc Netw. 2018 Jul; 16(7):795. PMID: 30006420.
      View in: PubMed
    2. Tempero M. Movin' On Up! J Natl Compr Canc Netw. 2018 Jun; 16(6):675. PMID: 29891517.
      View in: PubMed
    3. Tempero M. Getting Into the Weeds. J Natl Compr Canc Netw. 2018 May; 16(5):457. PMID: 29752317.
      View in: PubMed
    4. Tempero M. Standing Together or Alone. J Natl Compr Canc Netw. 2018 Apr; 16(4):341. PMID: 29632051.
      View in: PubMed
    5. Tempero M. Molecular Diagnostics: Another Battle Brewing. J Natl Compr Canc Netw. 2018 Mar; 16(3):225. PMID: 29523658.
      View in: PubMed
    6. Tempero M. Extending Our Reach-Will Telemedicine Get Us There? J Natl Compr Canc Netw. 2018 Feb; 16(2):107. PMID: 29439170.
      View in: PubMed
    7. Tempero M. Revisiting New Year's Resolutions. J Natl Compr Canc Netw. 2018 Jan; 16(1):1. PMID: 29295874.
      View in: PubMed
    8. Tempero M. It's About Time! J Natl Compr Canc Netw. 2017 Dec; 15(12):1443. PMID: 29223979.
      View in: PubMed
    9. Tempero M. Who's Watching the Kids? J Natl Compr Canc Netw. 2017 Nov; 15(11):1289. PMID: 29118220.
      View in: PubMed
    10. Tempero M. Introduction: Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies. Cancer J. 2017 Nov/Dec; 23(6):309. PMID: 29189324.
      View in: PubMed
    11. Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS. Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. Oncotarget. 2017 Nov 17; 8(58):97769-97786. PMID: 29228650.
      View in: PubMed
    12. Doherty GJ, Tempero M, Corrie PG. HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. Future Oncol. 2018 Jan; 14(1):13-22. PMID: 29235360.
      View in: PubMed
    13. Tempero M. Serving "a la CAR-T": Value-Based Pricing and Gene Therapy. J Natl Compr Canc Netw. 2017 Oct; 15(10):1179. PMID: 28982741.
      View in: PubMed
    14. Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, Womack MS, Xiong HQ, Waterhouse DM, Tempero M, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. Oncologist. 2017 Dec; 22(12):1427-e129. PMID: 28935773.
      View in: PubMed
    15. Tempero M. Your Genes: Getting the Best Fit. J Natl Compr Canc Netw. 2017 Sep; 15(9):1083. PMID: 28874592.
      View in: PubMed
    16. Tempero M, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Aug; 15(8):1028-1061. PMID: 28784865.
      View in: PubMed
    17. Tempero M. When It's Really Good, We Know It! J Natl Compr Canc Netw. 2017 Aug; 15(8):973. PMID: 28784856.
      View in: PubMed
    18. Tempero M. Reducing the Cost of Cancer Care: When Less Is More. J Natl Compr Canc Netw. 2017 Jul; 15(7):853. PMID: 28687571.
      View in: PubMed
    19. Tempero M. Getting Practical About Recertification. J Natl Compr Canc Netw. 2017 Jun; 15(6):753. PMID: 28596253.
      View in: PubMed
    20. Tempero M. Hospice: Angels at Work. J Natl Compr Canc Netw. 2017 05; 15(5):549. PMID: 28476733.
      View in: PubMed
    21. Tempero M. Active Systemic Treatment of Pancreatic Cancer. J Natl Compr Canc Netw. 2017 May; 15(5S):723-725. PMID: 28515255.
      View in: PubMed
    22. Tempero M. Politics as Usual-Not! J Natl Compr Canc Netw. 2017 04; 15(4):425. PMID: 28404753.
      View in: PubMed
    23. Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero M, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, Hanash SM. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. J Natl Cancer Inst. 2017 04 01; 109(4). PMID: 28376157.
      View in: PubMed
    24. Tempero M. Saying Yes. J Natl Compr Canc Netw. 2017 03; 15(3):277. PMID: 28275029.
      View in: PubMed
    25. Tempero M. Mad About MACRA. J Natl Compr Canc Netw. 2017 02; 15(2):137. PMID: 28188184.
      View in: PubMed
    26. Tempero M. New Year's Resolutions. J Natl Compr Canc Netw. 2017 01; 15(1):1. PMID: 28040714.
      View in: PubMed
    27. van Draanen J, Davidson P, Bour-Jordan H, Bowman-Carpio L, Boyle D, Dubinett S, Gardner B, Gardner J, McFall C, Mercola D, Nakazono T, Soares S, Stoppler H, Tempero M, Vandenberg S, Wan YJ, Dry S. Assessing Researcher Needs for a Virtual Biobank. Biopreserv Biobank. 2017 Jun; 15(3):203-210. PMID: 27929677.
      View in: PubMed
    28. Tempero M. An Oncologist's Letter to Santa. J Natl Compr Canc Netw. 2016 12; 14(12):1491. PMID: 27956532.
      View in: PubMed
    29. Humphris JL, Patch AM, Nones K, Bailey PJ, Johns AL, McKay S, Chang DK, Miller DK, Pajic M, Kassahn KS, Quinn MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Stone A, Wilson PJ, Anderson M, Fink JL, Holmes O, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Mead RS, Xu Q, Wu J, Pinese M, Cowley MJ, Jones MD, Nagrial AM, Chin VT, Chantrill LA, Mawson A, Chou A, Scarlett CJ, Pinho AV, Rooman I, Giry-Laterriere M, Samra JS, Kench JG, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, McKay CJ, Carter CR, Dickson EJ, Graham JS, Duthie F, Oien K, Hair J, Morton JP, Sansom OJ, Grützmann R, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Rusev B, Corbo V, Salvia R, Cataldo I, Tortora G, Tempero M. Hypermutation In Pancreatic Cancer. Gastroenterology. 2017 01; 152(1):68-74.e2. PMID: 27856273.
      View in: PubMed
    30. Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero M, Ko AH, Korn WM, Hwang J, Bergsland EK. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas. 2016 Nov; 45(10):1394-1400. PMID: 27171514.
      View in: PubMed
    31. Tempero M. My Knee Hurts! J Natl Compr Canc Netw. 2016 11; 14(11):1335. PMID: 27799504.
      View in: PubMed
    32. Tempero M. Crossing the Line. J Natl Compr Canc Netw. 2016 10; 14(10):1191. PMID: 27697973.
      View in: PubMed
    33. Tempero M. Hillary and Donald, Our Patients Are Watching. J Natl Compr Canc Netw. 2016 09; 14(9):1047. PMID: 27587617.
      View in: PubMed
    34. Tempero M. I'll Have Another Shot, Please! J Natl Compr Canc Netw. 2016 08; 14(8):929. PMID: 27496107.
      View in: PubMed
    35. Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero M, Ko AH. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? J Surg Oncol. 2016 Oct; 114(5):587-596. PMID: 27444658.
      View in: PubMed
    36. Tempero M. The Greatest Show on Earth! J Natl Compr Canc Netw. 2016 07; 14(7):813. PMID: 27407120.
      View in: PubMed
    37. Tempero M. Did the IRB Approve This? J Natl Compr Canc Netw. 2016 06; 14(6):699. PMID: 27283161.
      View in: PubMed
    38. Tempero M. Closely Guarded Secrets. J Natl Compr Canc Netw. 2016 05; 14(5):487. PMID: 27160226.
      View in: PubMed
    39. Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP. Pancreatic cancer. Nat Rev Dis Primers. 2016 04 21; 2:16022. PMID: 27158978.
      View in: PubMed
    40. Tempero M. Letting Nature Loose. J Natl Compr Canc Netw. 2016 Apr; 14(4):367. PMID: 27059185.
      View in: PubMed
    41. Ko AH, LoConte N, Tempero M, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016 Mar; 45(3):370-5. PMID: 26390428.
      View in: PubMed
    42. Tempero M. Promising the Moon! J Natl Compr Canc Netw. 2016 Mar; 14(3):237. PMID: 26957609.
      View in: PubMed
    43. Tempero M. Put Us Out of Business--Please! J Natl Compr Canc Netw. 2016 Feb; 14(2):123. PMID: 26850482.
      View in: PubMed
    44. Tempero M. Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies. J Oncol Pract. 2016 Jan; 12(1):29-30. PMID: 26759462.
      View in: PubMed
    45. Tempero M. Bringing Biosimilars to the Clinic: What's the Fuss? J Natl Compr Canc Netw. 2016 Jan; 14(1):1. PMID: 26733549.
      View in: PubMed
    46. Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, Gorjestani S, Liudahl SM, Truitt M, Olson P, Kim G, Hanahan D, Tempero M, Sheppard B, Irving B, Chang BY, Varner JA, Coussens LM. Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. Cancer Discov. 2016 Mar; 6(3):270-85. PMID: 26715645; PMCID: PMC4783268.
    47. Tempero M. Paying Less for High-Value Care--Are You Kidding Me? J Natl Compr Canc Netw. 2015 Dec; 13(12):1453. PMID: 26656513.
      View in: PubMed
    48. Tempero M. At Last: Getting Paid to Think! J Natl Compr Canc Netw. 2015 Nov; 13(11):1297. PMID: 26553759.
      View in: PubMed
    49. Tempero M. Putting an End to It! J Natl Compr Canc Netw. 2015 Oct; 13(10):1167. PMID: 26483055.
      View in: PubMed
    50. Tempero M. Crossing Over. J Natl Compr Canc Netw. 2015 Sep; 13(9):1053. PMID: 26358787.
      View in: PubMed
    51. Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero M, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res. 2016 Jan 01; 22(1):61-8. PMID: 26251290; PMCID: PMC4703532 [Available on 01/01/17].
    52. Tempero M. Move It! J Natl Compr Canc Netw. 2015 Aug; 13(8):939. PMID: 26285237.
      View in: PubMed
    53. Tempero M. Express Scripts? Really? J Natl Compr Canc Netw. 2015 Jul; 13(7):827. PMID: 26150575.
      View in: PubMed
    54. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero M, Bivona TG, Munster PN, Talasaz A, Collisson EA. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8. PMID: 26109333; PMCID: PMC4592417.
    55. Tempero M. Improving Access to Drugs--Big Pharma Comes to the Table. J Natl Compr Canc Netw. 2015 Jun; 13(6):703. PMID: 26085384.
      View in: PubMed
    56. Tempero M. Multidisciplinary management of pancreatic cancer. J Natl Compr Canc Netw. 2015 May; 13(5 Suppl):700-2. PMID: 25995435.
      View in: PubMed
    57. Tempero M. Reducing costs by changing behavior-really? J Natl Compr Canc Netw. 2015 May; 13(5):499. PMID: 25964633.
      View in: PubMed
    58. Tempero M. Turf war over diagnostic testing. J Natl Compr Canc Netw. 2015 Apr; 13(4):375. PMID: 25870372.
      View in: PubMed
    59. Tempero M. Putting precision medicine on the national agenda. J Natl Compr Canc Netw. 2015 Mar; 13(3):251. PMID: 25736000.
      View in: PubMed
    60. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrill LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamboni G, Tortora G, Tempero M. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015 Feb 26; 518(7540):495-501. PMID: 25719666.
      View in: PubMed
    61. Tempero M. All bundled up! J Natl Compr Canc Netw. 2015 Feb; 13(2):121. PMID: 25691601.
      View in: PubMed
    62. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero M, Wong SL, Somerfield MR, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015 Feb 20; 33(6):654-6. PMID: 25605844; PMCID: PMC4881372.
    63. Tempero M. Meet the New JNCCN! J Natl Compr Canc Netw. 2015 Jan; 13(1):1. PMID: 25583762.
      View in: PubMed
    64. Tempero M. Happy anniversary! J Natl Compr Canc Netw. 2014 Dec; 12(12):1653. PMID: 25505204.
      View in: PubMed
    65. Tempero M. Bringing science to clinical practice. J Natl Compr Canc Netw. 2014 Nov; 12(11):1495. PMID: 25361794.
      View in: PubMed
    66. Tempero M. Cancer screening: when is the juice worth the squeeze? J Natl Compr Canc Netw. 2014 Oct; 12(10):1359. PMID: 25313175.
      View in: PubMed
    67. Wang AS, Lodi A, Rivera LB, Izquierdo-Garcia JL, Firpo MA, Mulvihill SJ, Tempero M, Bergers G, Ronen SM. HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. NMR Biomed. 2014 Nov; 27(11):1361-70. PMID: 25199993.
      View in: PubMed
    68. Tempero M. Getting what you pay for: finding value in cancer care. J Natl Compr Canc Netw. 2014 Sep; 12(9):1199. PMID: 25190688.
      View in: PubMed
    69. Tempero M. Incentive-based oncology: unintended consequences? J Natl Compr Canc Netw. 2014 Aug; 12(8):1069. PMID: 25099438.
      View in: PubMed
    70. Tempero M, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014 Aug; 12(8):1083-93. PMID: 25099441.
      View in: PubMed
    71. Tempero M. A publicly funded clinical trials network: do we need it? J Natl Compr Canc Netw. 2014 Jul; 12(7):953. PMID: 24994914.
      View in: PubMed
    72. Tempero M. Embracing team-based oncology care. J Natl Compr Canc Netw. 2014 Jun; 12(6):845. PMID: 24925194.
      View in: PubMed
    73. Tempero M. Managing the fruits of our success. J Natl Compr Canc Netw. 2014 May; 12(5):603. PMID: 24812128.
      View in: PubMed
    74. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero M, Foster NR, Kim GP, Ko AH. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014 Apr; 43(3):343-9. PMID: 24622062.
      View in: PubMed
    75. Tempero M. The changing face of community practice: the new normal. J Natl Compr Canc Netw. 2014 Apr; 12(4):449. PMID: 24717562.
      View in: PubMed
    76. Tempero M. JNCCN going forward. J Natl Compr Canc Netw. 2014 Mar 01; 12(3):301. PMID: 24616533.
      View in: PubMed
    77. Paulson AS, Tran Cao HS, Tempero M, Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology. 2013 Jun; 144(6):1316-26. PMID: 23622141.
      View in: PubMed
    78. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero M, Wong SL, Prestrud AA, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Jun 10; 31(17):2189-204. PMID: 23669224.
      View in: PubMed
    79. Tempero M, Klimstra D, Berlin J, Hollingsworth T, Kim P, Merchant N, Moore M, Pleskow D, Wang-Gillam A, Lowy AM. Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Clin Cancer Res. 2013 Feb 01; 19(3):538-40. PMID: 23344262.
      View in: PubMed
    80. Cinar P, Tempero M. Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer J. 2012 Nov-Dec; 18(6):653-64. PMID: 23187854.
      View in: PubMed
    81. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rooman I, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Nones K, Fink JL, Christ A, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, Mead RS, Humphris JL, Kaplan W, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chou A, Chin VT, Chantrill LA, Mawson A, Samra JS, Kench JG, Lovell JA, Daly RJ, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012 Nov 15; 491(7424):399-405. PMID: 23103869; PMCID: PMC3530898.
    82. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero M. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7. PMID: 21552099.
      View in: PubMed
    83. Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero M. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2012 Dec; 70(6):875-81. PMID: 23053263.
      View in: PubMed
    84. Tempero M, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012 Jun 01; 10(6):703-13. PMID: 22679115; PMCID: PMC3807091.
    85. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero M, Spellman PT, Hanahan D, Gray JW. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011 Apr; 17(4):500-3. PMID: 21460848; PMCID: PMC3755490.
    86. Collisson E, Tempero M. Blinded by the light: molecular imaging in pancreatic adenocarcinoma. Clin Cancer Res. 2011 Jan 15; 17(2):203-5. PMID: 21106729.
      View in: PubMed
    87. Tempero M, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW, Malafa MP, Muscarella P, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA. Pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2010 Sep; 8(9):972-1017. PMID: 20876541; PMCID: PMC3135380.
    88. International network of cancer genome projects. Nature. 2010 Apr 15; 464(7291):993-8. PMID: 20393554.
      View in: PubMed
    89. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero M. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7. PMID: 20130876.
      View in: PubMed
    90. Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 2009 Nov 20; 27(33):5660-9. PMID: 19858397.
      View in: PubMed
    91. Kulke MH, Tempero M, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20; 27(33):5506-12. PMID: 19858396; PMCID: PMC2792952.
    92. Ko AH, Tempero M. Personalized medicine for pancreatic cancer: a step in the right direction. Gastroenterology. 2009 Jan; 136(1):43-5. PMID: 19041649.
      View in: PubMed
    93. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero M. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008 Oct; 37(3):269-74. PMID: 18815548.
      View in: PubMed
    94. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero M. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008 Oct; 26(5):463-71. PMID: 18379729.
      View in: PubMed
    95. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero M. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest. 2008 Feb; 26(1):47-52. PMID: 18181045.
      View in: PubMed
    96. Tempero M. How I treat pancreatic ductal adenocarcinoma. J Oncol Pract. 2008 Jan; 4(1):46-7. PMID: 20859443; PMCID: PMC2793930.
    97. Tempero M, Arnoletti JP, Ben-Josef E, Bhargava P, Casper ES, Kim P, Malafa MP, Nakakura EK, Shibata S, Talamonti M, Wang H, Willett C. Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2007 Nov; 5(10):998-1033. PMID: 18053426.
      View in: PubMed
    98. Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Haustermans K, Heinemann V, Hoff P, Johnston PG, Kerr D, Labianca R, Louvet C, Minsky B, Moore M, Nordlinger B, Pedrazzoli S, Roth A, Rothenberg M, Rougier P, Schmoll HJ, Tabernero J, Tempero M, van de Velde C, Van Laethem JL, Zalcberg J. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol. 2007 Jun; 18 Suppl 7:vii1-vii10. PMID: 17600091.
      View in: PubMed
    99. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero M. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):809-16. PMID: 17363191.
      View in: PubMed
    100. Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark. 2007; 3(1):1-33. PMID: 17655039.
      View in: PubMed
    101. Jhawer M, Rosen L, Dancey J, Hochster H, Hamburg S, Tempero M, Clendeninn N, Mani S. Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2007 Feb; 25(1):85-94. PMID: 16957834.
      View in: PubMed
    102. Hruban RH, Rustgi AK, Brentnall TA, Tempero M, Wright CV, Tuveson DA. Pancreatic cancer in mice and man: the Penn Workshop 2004. Cancer Res. 2006 Jan 01; 66(1):14-7. PMID: 16397208.
      View in: PubMed
    103. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero M. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2006 Jan 20; 24(3):379-85. PMID: 16344320.
      View in: PubMed
    104. Ko AH, Tempero M. Systemic therapy for pancreatic cancer. Semin Radiat Oncol. 2005 Oct; 15(4):245-53. PMID: 16183478.
      View in: PubMed
    105. Tempero M, Behrman S, Ben-Josef E, Benson AB, Cameron JL, Casper ES, Hoffman JP, Karl RC, Kim P, Koh WJ, Kuvshinoff BW, Melvin WS, Muscarella P, Sasson AR, Shibata S, Shrieve DC, Talamonti MS, Tyler DS, Vickers SM, Warren RS, Willett C, Wolff RA. Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2005 Sep; 3(5):598-626. PMID: 16194453.
      View in: PubMed
    106. Ko AH, Tempero M. Treatment of metastatic pancreatic cancer. J Natl Compr Canc Netw. 2005 Sep; 3(5):627-36. PMID: 16194454.
      View in: PubMed
    107. Tempero M. Clinical oncology 2004: the president's report. J Clin Oncol. 2004 Nov 15; 22(22):4437-41. PMID: 15542796.
      View in: PubMed
    108. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003 Sep 15; 21(18):3402-8. PMID: 12885837.
      View in: PubMed
    109. Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero M. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer. 2003; 34(2-3):107-16. PMID: 15361643.
      View in: PubMed
    110. Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B, McCashland T, Sorrell M, Tempero M, Langnas A. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant. 2002 Sep; 2(8):774-9. PMID: 12243499.
      View in: PubMed
    111. Kurizaki T, Okazaki S, Sanderson SD, Colcher D, Enke CA, Tempero M, Baranowska-Kortylewicz J. Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a. J Nucl Med. 2002 Jul; 43(7):957-67. PMID: 12097469.
      View in: PubMed
    112. Ko AH, Tempero M. Current and future strategies for combined-modality therapy in pancreatic cancer. Curr Oncol Rep. 2002 May; 4(3):202-12. PMID: 11937010.
      View in: PubMed
    113. Augustine SC, Norenberg JP, Colcher DM, Vose JM, Gobar LS, Dukat VJ, Hohenstein MA, Rutar FJ, Jacobson DA, Tempero M. Combination therapy for non-Hodgkin's lymphoma: an opportunity for pharmaceutical care in a specialty practice. J Am Pharm Assoc (Wash). 2002 Jan-Feb; 42(1):93-100. PMID: 11833524.
      View in: PubMed
    114. Pour PM, Tempero M, Takasaki H, Uchida E, Takiyama Y, Burnett DA, Steplewski Z. Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type. Cancer Res. 1988 Oct 01; 48(19):5422-6. PMID: 3166398.
      View in: PubMed
    115. Tempero M. Bile acids, ornithine decarboxylase, and cell proliferation in colon cancer: a review. Dig Dis. 1986; 4(1):49-56. PMID: 3545561.
      View in: PubMed